Personal information

Activities

Employment (1)

Memorial Sloan Kettering Cancer Center: New York, US

2011-07 to present
Employment
Source: check_circle
Memorial Sloan Kettering Cancer Center

Education and qualifications (1)

New York University: New York, New York, US

2004-08 to 2008-05
Qualification
Source: Self-asserted source
Christopher Forlenza

Works (13)

Combination Brentuximab Vedotin and Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma.

Blood advances
2021-09-24 | Journal article
Source: Self-asserted source
Christopher Forlenza

Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors.

Nature cancer
2021-02-15 | Journal article
Source: Self-asserted source
Christopher Forlenza

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL.

Blood
2019-12-01 | Journal article
Source: Self-asserted source
Christopher Forlenza

Using genomic data for selecting the treatment of lymphoma patients.

Current opinion in hematology
2019-07-01 | Journal article
Source: Self-asserted source
Christopher Forlenza

A case of <i>KMT2A-SEPT9</i> fusion-associated acute megakaryoblastic leukemia.

Cold Spring Harbor molecular case studies
2018-12-17 | Journal article
Source: Self-asserted source
Christopher Forlenza

Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis.

Pediatric blood & cancer
2018-10-18 | Journal article
Source: Self-asserted source
Christopher Forlenza

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

British journal of haematology
2017-10-29 | Journal article
Source: Self-asserted source
Christopher Forlenza

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2016-04-11 | Journal article
Source: Self-asserted source
Christopher Forlenza

Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2016-01-06 | Journal article
Source: Self-asserted source
Christopher Forlenza

Myeloablative chemotherapy with autologous stem cell transplant for desmoplastic small round cell tumor

Sarcoma
2015 | Journal article
Contributors: Forlenza, C. J.; Kushner, B. H.; Kernan, N.; Boulad, F.; Magnan, H.; Wexler, L.; Wolden, S. L.; LaQuaglia, M. P.; Modak, S.
Source: check_circle
Memorial Sloan Kettering Cancer Center

Busulfan, melphalan, and thiotepa conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) of pediatric patients with acute leukemia and central nervous system (CNS) disease

Biology of Blood and Marrow Transplantation
2014-02-01 | Conference abstract
SOURCE-WORK-ID:

51182

Contributors: Forlenza, C. J.; Kobos, R.; Kernan, N. A.; Scaradavou, A.; Prockop, S. E.; Curran, K.; Shukla, N.; Steinherz, P. G.; O'reilly, R.; Boulad, F.
Source: check_circle
Memorial Sloan Kettering Cancer Center

Pathology turnaround time in pediatric oncology: A tool to prepare patients and families for the diagnostic waiting period

Journal of Pediatric Hematology/Oncology
2013-10-01 | Journal article
Contributors: Forlenza, C. J.; Levy, A. S.
Source: check_circle
Memorial Sloan Kettering Cancer Center

Live (vaccines) from New York

Bone Marrow Transplantation
2013-06-01 | Journal article
Contributors: Forlenza, C. J.; Small, T. N.
Source: check_circle
Memorial Sloan Kettering Cancer Center